John William Wulf Buys 81,000 Shares of Agilon Health (NYSE:AGL) Stock

Agilon Health, Inc. (NYSE:AGL) Director John William Wulf bought 81,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were acquired at an average cost of $0.63 per share, with a total value of $51,030.00. Following the completion of the purchase, the director owned 365,857 shares of the company’s stock, valued at approximately $230,489.91. The trade was a 28.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Agilon Health Stock Performance

Shares of AGL traded down $0.03 during trading hours on Friday, hitting $0.84. 6,296,853 shares of the company were exchanged, compared to its average volume of 6,084,399. The firm has a fifty day simple moving average of $0.77 and a 200-day simple moving average of $1.04. Agilon Health, Inc. has a one year low of $0.51 and a one year high of $6.08.

Agilon Health (NYSE:AGL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.09). The company had revenue of $1.44 billion during the quarter, compared to analyst estimates of $1.43 billion. Agilon Health had a negative net margin of 5.24% and a negative return on equity of 75.92%. As a group, equities analysts predict that Agilon Health, Inc. will post -0.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Agilon Health

A number of large investors have recently bought and sold shares of the company. AQR Capital Management LLC boosted its holdings in shares of Agilon Health by 243.3% during the 1st quarter. AQR Capital Management LLC now owns 501,440 shares of the company’s stock valued at $2,171,000 after acquiring an additional 355,365 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Agilon Health by 3.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 214,200 shares of the company’s stock worth $927,000 after acquiring an additional 7,209 shares in the last quarter. Dynamic Technology Lab Private Ltd increased its position in shares of Agilon Health by 28.4% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 47,111 shares of the company’s stock valued at $204,000 after purchasing an additional 10,424 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Agilon Health by 6.6% in the first quarter. Goldman Sachs Group Inc. now owns 5,060,333 shares of the company’s stock valued at $21,911,000 after buying an additional 311,158 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Agilon Health by 5.6% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 105,324 shares of the company’s stock worth $256,000 after acquiring an additional 5,627 shares in the last quarter.

Agilon Health News Summary

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Agilon director John William Wulf bought 81,000 AGL shares (avg. $0.63) in November, increasing his stake by ~28%—an insider purchase investors often view as a sign of confidence. Insider Form 4
• Neutral Sentiment: Brokerage consensus remains lukewarm: recent coverage shows an average recommendation of “Hold,” suggesting analysts are cautious but not uniformly bearish. Analyst Consensus
• Negative Sentiment: Bronstein, Gewirtz & Grossman filed/urged investors to act in a class action alleging investor harm against Agilon and certain officers—adds to legal exposure and headline risk. Bronstein, Gewirtz & Grossman filing
• Negative Sentiment: Faruqi & Faruqi says it is investigating claims on behalf of Agilon investors and is soliciting potential class members—more counsel activity increases likelihood of consolidated litigation and potential discovery/settlement costs. Faruqi & Faruqi notice
• Negative Sentiment: Multiple other plaintiff firms (Rosen, Levi & Korsinsky, Bernstein Liebhard, Pomerantz, The Gross Law Firm) have filed or issued shareholder alerts reminding investors of lead?plaintiff deadlines—this sustained outreach keeps Agilon in the legal headlines and may pressure the stock. Rosen Law Firm notice Levi & Korsinsky notice Bernstein Liebhard notice Pomerantz notice The Gross Law Firm notice

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AGL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, January 21st. Barclays decreased their price target on shares of Agilon Health from $1.50 to $1.00 and set an “underweight” rating for the company in a report on Thursday, November 6th. BTIG Research reiterated a “neutral” rating on shares of Agilon Health in a report on Friday, December 12th. Wells Fargo & Company cut their price target on shares of Agilon Health from $1.50 to $1.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Finally, Royal Bank Of Canada raised shares of Agilon Health from a “hold” rating to a “moderate buy” rating in a report on Wednesday, December 3rd. Four investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $2.71.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.